Dr Reddy’s gets DCGI nod for Zytorvi in advanced esophageal cancer
viaeconomictimes.indiatimes.com21 Oct
Dr Reddy’s Laboratories has received approval for Zytorvi, an immunotherapy targeting advanced esophageal squamous cell carcinoma. This new indication allows treatment for adult patients with a combination of toripalimab, cisplatin, and paclitaxel. Approximately 80 percent of esophageal cancer…
Khabar Adda curates headlines like this across Top Stories, Entertainment, Bollywood, Hollywood, Crime and Politics from public RSS feeds. This page links out to economictimes.indiatimes.com's own reporting rather than reproducing it — the excerpt above comes from economictimes.indiatimes.com's own feed.
Read the full story on economictimes.indiatimes.com ↗